<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04495257</url>
  </required_header>
  <id_info>
    <org_study_id>2000026830</org_study_id>
    <nct_id>NCT04495257</nct_id>
  </id_info>
  <brief_title>A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)</brief_title>
  <official_title>A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apexigen America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, open-label, single institution, dose escalation and dose expansion&#xD;
      study to evaluate the efficacy, safety, and tolerability of APX005M in combination with&#xD;
      nivolumab and ipilimumab in patients with advanced melanoma and RCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a phase 1 study to evaluate the safety and tolerability of APX005M in&#xD;
      combination with nivolumab and ipilimumab. The study will enroll patients with advanced solid&#xD;
      tumors (melanoma, RCC) to determine the recommended phase II dosing (RP2D) of APX005M in&#xD;
      combination with ipilimumab 1mg/kg and nivolumab 3 mg/kg (IPI1 NIVO3) every 3 weeks for four&#xD;
      cycles followed by APX005M in combination with nivolumab 360mg every 3 weeks. APX005M will be&#xD;
      administered at a dose of 0.1 mg/kg every 3 weeks in Dose Level 1 (DL1) and escalated to 0.3&#xD;
      mg/kg every 3 weeks in Dose Level 2 (DL2) (Table 1). The IPI1 NIVO3 regimen is approved for&#xD;
      patients with metastatic RCC.&#xD;
&#xD;
      APX005M is a humanized IgG1 agonistic monoclonal antibody that binds CD40. Nivolumab is a&#xD;
      humanized IgG4 monoclonal antibody directed against PD-1. Ipilimumab is a humanized IgG1κ&#xD;
      monoclonal antibody directed against CTLA-4.&#xD;
&#xD;
      Primary Objective&#xD;
&#xD;
        -  To assess the safety and tolerability of APX005M in combination with nivolumab and&#xD;
           ipilimumab&#xD;
&#xD;
        -  To determine the recommended RP2D of APX005M in combination with nivolumab and&#xD;
           ipilimumab in patients with unresectable metastatic melanoma or renal cell carcinoma.&#xD;
&#xD;
      Secondary Objective&#xD;
&#xD;
      • Determine rate and pattern of AEs in patients treated with APX005M in combination with&#xD;
      nivolumab and ipilimumab&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The safety and tolerability of APX005M in combination with nivolumab and ipilimumab will be assessed by monitoring the of dose-limiting toxicities (DLTs) . This will be defined by both DLTs and any of the following AEs (graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v5.0) which occur during the first 9 weeks of ipilimumab + nivolumab + APX005M administration that is not clearly due to a cause other than study medication. DLTs in this study do not include reversible grade 3-4 irAEs, that are acceptable and expected with treatment regimens containing ipilimumab and nivolumab, but do include severe, irreversible, non-endocrine adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose of APX005M</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>This outcome will determine the recommended phase II dose (RP2D) of APX005M in combination with nivolumab and ipilimumab in patients with unresectable or metastatic melanoma or renal cell carcinoma (RCC). The RP2D will be defined as a triplet regimen that does not exceed a grade 3-4 irAE rate of approximately 55% or lead to a significant increase in dose limiting toxicities (DLTs) specific to an ipilimumab + nivolumab containing regimen, particularly those which are severe, irreversible, and non-endocrine related events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The rate of AEs in patients treated with APX005M in combination with nivolumab and ipilimumab will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Frequency</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The frequency of AE type in patients treated with APX005M in combination with nivolumab and ipilimumab will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced Melanoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Level 1 (DL1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DL1 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.1mg/kg for the induction phase. After 4 cycles, participants will be treated with 360mg of nivolumab and APX005M every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2 (DL2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DL2 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.3mg/kg for the induction phase. After 4 cycles we will treat with 360mg of nivolumab and APX005M every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter</description>
    <arm_group_label>Dose Level 1 (DL1)</arm_group_label>
    <arm_group_label>Dose Level 2 (DL2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments</description>
    <arm_group_label>Dose Level 1 (DL1)</arm_group_label>
    <arm_group_label>Dose Level 2 (DL2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX005M</intervention_name>
    <description>APX005M 0.3mg/kg intravenously (IV) every 3 weeks</description>
    <arm_group_label>Dose Level 1 (DL1)</arm_group_label>
    <arm_group_label>Dose Level 2 (DL2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. At least 1 site of disease must be accessible to provide repeat biopsies for tumor&#xD;
             tissue. The biopsy may be waived if not feasible upon discussion with the study PIs.&#xD;
             This site may be a target lesion as long as it will not be rendered unmeasurable by&#xD;
             the biopsy procedure.&#xD;
&#xD;
             2. Age ≥18, able to understand and sign the informed consent form 3. ECOG performance&#xD;
             status &lt; 2 4. No prior systemic immune therapy for advanced (unresectable) disease.&#xD;
             Prior targeted therapy is allowed. Adjuvant therapy is allowed provided that at least&#xD;
             6 months have lapsed from the last dose of an immune checkpoint inhibitor. Prior small&#xD;
             molecule inhibitors must be discontinued within 2 weeks before starting study.&#xD;
&#xD;
             5. Life expectancy of at least 6 months 6. A history of previously treated brain&#xD;
             metastases is allowed, provided that they are stable for at least 4 weeks.&#xD;
&#xD;
             7. Willingness to undergo tumor biopsy (if amenable) prior to initiation of therapy&#xD;
             and on trial.&#xD;
&#xD;
             8. Willingness to provide an archival specimen block, if available, for research 9.&#xD;
             Normal organ function . 10. Female subjects of childbearing potential should have a&#xD;
             negative urine or serum pregnancy within 24 hours prior to receiving the first dose of&#xD;
             study medication. If the urine test is positive or cannot be confirmed as negative, a&#xD;
             serum pregnancy test will be required.&#xD;
&#xD;
             11. Female subjects of childbearing potential should be willing to use a highly&#xD;
             effective contraception (hormonal or IUD) or be surgically sterile, or abstain from&#xD;
             heterosexual activity for a period of at least 5 months after the last dose of study&#xD;
             drug. Subjects of childbearing potential are those who have not been surgically&#xD;
             sterilized or have not been free from menses for &gt; 1 year.&#xD;
&#xD;
             12. Male subjects should agree to use an adequate method of contraception starting&#xD;
             with the first dose of study therapy through at least 7 months after the last dose of&#xD;
             study drug.&#xD;
&#xD;
             13. Patients must have at least one measurable lesion at baseline by computed&#xD;
             tomography (CT) or magnetic resonance imaging (MRI) as per RECIST v1.1 criteria. Tumor&#xD;
             sites situated in a previously irradiated area, or in an area subjected to other&#xD;
             loco-reginal therapy, are not considered measurable unless there has been demonstrated&#xD;
             progression in the lesion.&#xD;
&#xD;
             14. Prior focal radiotherapy is allowed. Radiation to pulmonary or intestinal sites&#xD;
             must be completed at least 1 week prior to study Day 1. Radiation to the brain must be&#xD;
             completed within 4 weeks prior to initiation of treatment. There is no time&#xD;
             restriction prior to study Day 1 for patients who have received radiation to bone,&#xD;
             soft tissue or other sites. No radiopharmaceuticals (strontium, samarium) within 8&#xD;
             weeks before first dose of study drug administration.&#xD;
&#xD;
             15. Major surgery must be completed at least 2 weeks prior to the first dose of study&#xD;
             drug administration and patients should have recovered. Wounds must be healed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Untreated brain metastases. 2. A patient who has had prior treatment with immune&#xD;
             therapy for advanced disease. Prior immune checkpoint inhibitors as adjuvant therapy&#xD;
             is allowed provided at least 6 months have lapsed from the last dose. Prior targeted&#xD;
             therapy is allowed as long as 2 weeks have passed.&#xD;
&#xD;
             3. Use of corticosteroids to control immune related adverse events at enrollment will&#xD;
             not be allowed, and patients who previously required corticosteroids for symptom&#xD;
             control must be off steroids for at least 2 weeks. Low-dose steroid use (≤10 mg of&#xD;
             prednisone or equivalent) as corticosteroid replacement therapy for primary or&#xD;
             secondary adrenal insufficiency is allowed.&#xD;
&#xD;
             4. Has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to prior&#xD;
             treatments with the exceptions such as alopecia listed in Table 2.&#xD;
&#xD;
             5. History of grade 3-4 neurologic or cardiac toxicity or life-threatening liver&#xD;
             toxicity poorly responsive to steroids with prior anti-PD-1/anti-PD-L1 therapy in the&#xD;
             adjuvant setting.&#xD;
&#xD;
             6. Presence of leptomeningeal disease. 7. Has active autoimmune disease unrelated to&#xD;
             use of immune checkpoint inhibitors that has required systemic treatment in the past&#xD;
             year (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
             8. Pregnancy or breast feeding. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately. Because there is an unknown but potential risk for adverse events in&#xD;
             nursing infants secondary to treatment of the mother with nivolumab, ipilimumab or&#xD;
             APX005M, breastfeeding must be discontinued if the mother is enrolled on this trial.&#xD;
&#xD;
             9. Patients may not be receiving any other investigational agents and may not have&#xD;
             participated in a study of an investigational agent or using an investigational device&#xD;
             within 4 weeks of the first dose of treatment.&#xD;
&#xD;
             10. Either a concurrent condition (including medical illness, such as active infection&#xD;
             requiring treatment with intravenous antibiotics or the presence of laboratory&#xD;
             abnormalities) or history of a prior condition that places the patient at unacceptable&#xD;
             risk if he/she were treated with the study drug or a medical condition that confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
             11. Concurrent, active malignancies in addition to those being studied (other than&#xD;
             cutaneous squamous cell carcinoma or basal cell carcinoma).&#xD;
&#xD;
             12. Active (non-infectious) pneumonitis. 13. Has a known Human Immunodeficiency Virus&#xD;
             (HIV), Hepatitis B (HBV), or Hepatitis C (HCV) acute or chronic infection.&#xD;
&#xD;
             14. Has received a live vaccine within 30 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
             15. History of myocardial infarction or unstable angina within 3 months prior to Cycle&#xD;
             1, Day 1.&#xD;
&#xD;
             16. Prisoners, or subjects who are under compulsory detention 17. Open wounds and&#xD;
             active skin infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harriet Kluger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kelly Olino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harriet Kluger, MD</last_name>
    <phone>(203) 200-6622</phone>
    <email>harriet.kluger@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neta Shanwetter Levit, MPH</last_name>
    <phone>(203) 500-0834</phone>
    <email>Neta.shanwetterlevit@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harriet Kluger, MD</last_name>
      <phone>203-200-6622</phone>
      <email>harriet.kluger@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Neta Shanwetter Levit, MPH</last_name>
      <email>Neta.shanwetterlevit@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Harriet Kluger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harriet Kluger, MD</last_name>
      <phone>203-200-6622</phone>
      <email>harriet.kluger@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Neta Shanwetter Levit, MPH</last_name>
      <phone>(203) 500-0834</phone>
      <email>neta.shanwetterlevit@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Harriet Kluger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Weiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Olino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>August 13, 2023</last_update_submitted>
  <last_update_submitted_qc>August 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Harriet Kluger</investigator_full_name>
    <investigator_title>Professor of Medicine (Medical Oncology)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04495257
org study id: 2000026830
nct id: NCT04495257
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This study is a Phase 1, open-label, single institution, dose escalation and dose expansion
      study to evaluate the efficacy, safety, and tolerability of APX005M in combination with
      nivolumab and ipilimumab in patients with advanced melanoma and RCC.
This trial is a phase 1 study to evaluate the safety and tolerability of APX005M in
      combination with nivolumab and ipilimumab. The study will enroll patients with advanced solid
      tumors (melanoma, RCC) to determine the recommended phase II dosing (RP2D) of APX005M in
      combination with ipilimumab 1mg/kg and nivolumab 3 mg/kg (IPI1 NIVO3) every 3 weeks for four
      cycles followed by APX005M in combination with nivolumab 360mg every 3 weeks. APX005M will be
      administered at a dose of 0.1 mg/kg every 3 weeks in Dose Level 1 (DL1) and escalated to 0.3
      mg/kg every 3 weeks in Dose Level 2 (DL2) (Table 1). The IPI1 NIVO3 regimen is approved for
      patients with metastatic RCC.

      APX005M is a humanized IgG1 agonistic monoclonal antibody that binds CD40. Nivolumab is a
      humanized IgG4 monoclonal antibody directed against PD-1. Ipilimumab is a humanized IgG1κ
      monoclonal antibody directed against CTLA-4.

      Primary Objective

        -  To assess the safety and tolerability of APX005M in combination with nivolumab and
           ipilimumab

        -  To determine the recommended RP2D of APX005M in combination with nivolumab and
           ipilimumab in patients with unresectable metastatic melanoma or renal cell carcinoma.

      Secondary Objective

      • Determine rate and pattern of AEs in patients treated with APX005M in combination with
      nivolumab and ipilimumab
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Dose-limiting toxicities
time frame: Up to 2 years
description: The safety and tolerability of APX005M in combination with nivolumab and ipilimumab will be assessed by monitoring the of dose-limiting toxicities (DLTs) . This will be defined by both DLTs and any of the following AEs (graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v5.0) which occur during the first 9 weeks of ipilimumab + nivolumab + APX005M administration that is not clearly due to a cause other than study medication. DLTs in this study do not include reversible grade 3-4 irAEs, that are acceptable and expected with treatment regimens containing ipilimumab and nivolumab, but do include severe, irreversible, non-endocrine adverse events
measure: Recommended dose of APX005M
time frame: Up to 2 years
description: This outcome will determine the recommended phase II dose (RP2D) of APX005M in combination with nivolumab and ipilimumab in patients with unresectable or metastatic melanoma or renal cell carcinoma (RCC). The RP2D will be defined as a triplet regimen that does not exceed a grade 3-4 irAE rate of approximately 55% or lead to a significant increase in dose limiting toxicities (DLTs) specific to an ipilimumab + nivolumab containing regimen, particularly those which are severe, irreversible, and non-endocrine related events.
measure: Adverse Events Rate
time frame: Up to 2 years
description: The rate of AEs in patients treated with APX005M in combination with nivolumab and ipilimumab will be assessed.
measure: Adverse Events Frequency
time frame: Up to 2 years
description: The frequency of AE type in patients treated with APX005M in combination with nivolumab and ipilimumab will be assessed.
arm group label: Dose Level 1 (DL1)
arm group type: Experimental
description: DL1 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.1mg/kg for the induction phase. After 4 cycles, participants will be treated with 360mg of nivolumab and APX005M every 3 weeks.
arm group label: Dose Level 2 (DL2)
arm group type: Experimental
description: DL2 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.3mg/kg for the induction phase. After 4 cycles we will treat with 360mg of nivolumab and APX005M every 3 weeks.
intervention type: Drug
intervention name: Nivolumab
description: Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
arm group label: Dose Level 1 (DL1)
arm group label: Dose Level 2 (DL2)
intervention type: Drug
intervention name: Ipilimumab
description: Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
arm group label: Dose Level 1 (DL1)
arm group label: Dose Level 2 (DL2)
intervention type: Drug
intervention name: APX005M
description: APX005M 0.3mg/kg intravenously (IV) every 3 weeks
arm group label: Dose Level 1 (DL1)
arm group label: Dose Level 2 (DL2)
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Harriet Kluger, MD
role: Principal Investigator
affiliation: Yale University
last name: Sarah Weiss, MD
role: Principal Investigator
affiliation: Yale University
last name: Kelly Olino, MD
role: Principal Investigator
affiliation: Yale University
last name: Harriet Kluger, MD
phone: (203) 200-6622
email: harriet.kluger@yale.edu
last name: Neta Shanwetter Levit, MPH
phone: (203) 500-0834
email: Neta.shanwetterlevit@yale.edu
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: Yale University
investigator full name: Harriet Kluger
investigator title: Professor of Medicine (Medical Oncology)
mesh term: Carcinoma
mesh term: Melanoma
mesh term: Carcinoma, Renal Cell
mesh term: Nivolumab
mesh term: Ipilimumab
sharing ipd: No